Akesobio Australia Pty Ltd
Quick facts
Phase 3 pipeline
- AK120 · Oncology
AK120 is an engineered T cell engager that redirects patient T cells to recognize and eliminate cancer cells expressing specific tumor antigens.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: